Back to Search
Start Over
Linear IgA bullous dermatosis successfully treated with omalizumab: A case report
- Source :
- JAAD Case Reports
- Publication Year :
- 2019
- Publisher :
- Elsevier, 2019.
-
Abstract
- Linear IgA bullous dermatosis (LABD) is a rare autoimmune bullous disease characterized by linear deposition of IgA along the cutaneous basement membrane. Clinically, LABD has a variable presentation characterized by tense vesiculobullous lesions on the trunk and extremities that often appear in a herpetiform arrangement or at the center of annular erythematous plaques. Omalizumab (Xolair; Genentech, South San Francisco, CA) is a monoclonal anti–immunoglobulin E (IgE) antibody that has been approved for chronic idiopathic urticaria (CIU). To date, omalizumab has not been reported to be of benefit in the treatment of LABD. However, omalizumab has been reported to improve control of other bullous dermatoses, particularly bullous pemphigoid.1
- Subjects :
- medicine.medical_specialty
Linear IgA bullous dermatosis
Case Report
Dermatology
Omalizumab
Immunoglobulin E
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Erythematous plaque
bullous dermatosis
Herpetiform
Bullous disease
Medicine
skin and connective tissue diseases
CIU, chronic idiopathic urticaria
IgE, immunoglobulin E
integumentary system
biology
treatment
business.industry
LABD, linear IgA bullous dermatosis
medicine.disease
eye diseases
monoclonal anti-IgE antibody
030220 oncology & carcinogenesis
Monoclonal
biology.protein
omalizumab
sense organs
Chronic idiopathic urticaria
IgE
linear IgA bullous dermatosis
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 23525126
- Volume :
- 5
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- JAAD Case Reports
- Accession number :
- edsair.doi.dedup.....879c0f460093a75bea6d0adc741a53db